QUALITY & SAFETY
ISO 13485, ISO 14971, ISO 9001
MARK II / SOVEREIGN CONSTELLATION
6 JURISDICTIONS RENDERED, 15 UNDER FILING STRATEGY
ERIONEX INC. is a Canadian federal corporation building ERIONEX OS: not a point solution, not an integration layer, but foundational infrastructure that treats drug discovery, clinical trials, regulatory compliance, manufacturing intelligence, and real-world evidence as one sovereign, AI-native system rather than six disconnected ones. The company operates at the intersection of pharmaceutical science, clinical research, cloud architecture, artificial intelligence, and cryptographic sovereignty.
The legal entity: Federal Corporation No. 1771030-5, headquartered in Mississauga, Ontario, holder of the IP estate and the parent company that builds and operates ERIONEX OS.
A product of ERIONEX INC.: the Unified Therapeutic Intelligence Operating System (UTIOS), 19 planes across 7 layers, specified in 16 volumes, 144 chapters, 38 appendices.
ERIONEX OS is a 19-plane, 7-layer, AI-native Unified Therapeutic Intelligence Operating System (UTIOS) unifying drug discovery, clinical operations, regulatory affairs, manufacturing intelligence, and real-world evidence under one architecture, specified across 16 volumes and 144 chapters, and defended by a six-family provisional patent estate of 83+ claims.
Holistic Therapeutics-as-a-Service: the commercial surface through which sponsors, CROs, and regulators consume ERIONEX OS capability without operating the underlying infrastructure themselves.
The reasoning substrate connecting discovery, clinical, regulatory, and real-world-evidence data into a single queryable graph rather than siloed records.
11 current-generation planes, 3 bridge planes, and 6 future-generation planes, with P17 spanning bridge and future-generation tiers through its dual configuration.
Figures reconciled against the Master Specification Blueprint v5.4 (16 volumes) as the authoritative source of record.
Data residency and cryptographic control stay with the jurisdiction and institution that generated the data, not with ERIONEX.
One architecture for discovery through real-world evidence, rather than point systems stitched together after the fact.
Governance, assurance, and recursive assurance are dedicated architecture planes, not an audit layer bolted on afterward.
Every figure on this page traces to a numbered section of the Master Specification Blueprint v5.4.
A sovereign and federated infrastructure model lets institutions participate without surrendering custody of their data.
Architecture decisions are filed as they are made: six provisional patent families, 83+ claims, before the platform ships.
Structural overview only. Click a plane for its function; no implementation detail, control configuration, or claim language is disclosed here.
Filed across the United States, European Patent Office, Japan, China, Canada, South Korea, and Australia, ahead of the fifteen-jurisdiction filing strategy.
OIN membership confirmed March 12, 2026. LOT Network membership confirmed March 18, 2026, extending defensive coverage against patent assertion entities.
MVP validated in a laboratory environment, ahead of field and operational validation stages.
Category-level view of the compliance frameworks the architecture is designed against. Full control mappings are disclosed under NDA.
Resilience, security, and assurance measures specified across the architecture, reconciled to the Master Specification Blueprint v5.4.
Cross-cutting programmes: Falco + Tetragon eBPF runtime security, SLSA Level 4 supply chain security, and chaos engineering.
Founder, ERIONEX INC.
Eric founded ERIONEX INC. to apply enterprise-architecture discipline to a sector that has historically integrated rather than unified its systems. The 16-volume Master Specification Blueprint, now at v5.4, reflects a specification-first approach uncommon among venture-stage platform companies: architecture and intellectual property are filed and formalized before the platform is commercialized.
Chief Medical Officer
High Point, North Carolina, USA
Board-certified internist and Fellow of the American College of Physicians and Society of Hospital Medicine, bringing deep clinical expertise in internal medicine and hospital-based care to guide ERIONEX OS's medical intelligence and clinical decision support architecture.
Director of Clinical Operations
Union, Kentucky, USA
Multidisciplinary clinical leader combining doctoral-level epidemiology, public health expertise, and frontline nursing practice to lead clinical operations strategy, bridging discovery-stage intelligence with real-world clinical execution.
Director of Regulatory Affairs
Huntingdon, Cambridge, UK
Regulatory affairs leader with doctoral and master's-level scientific expertise, positioned to navigate the regulatory frameworks of Health Canada, the EMA, MHRA, and the CPTPP member jurisdictions that ERIONEX OS is architecturally designed to serve simultaneously.
Positioned within the Comprehensive and Progressive Agreement for Trans-Pacific Partnership trade and IP framework.
Canadian data residency and cryptographic sovereignty are architecture requirements, not regional configuration options.
Domestic filing coordinated with the Canadian Intellectual Property Office alongside the international patent family.
Open Invention Network membership confirmed March 12, 2026; LOT Network membership confirmed March 18, 2026.
Operating within Canada's federal and provincial life-sciences and deep-tech funding ecosystem.
Corporation No. 1771030-5, headquartered in Mississauga, Ontario.
ERIONEX INC. incorporated federally under Corporation No. 1771030-5.
16-volume architecture specification initiated, now reconciled at v5.4: 144 chapters, 38 appendices.
Six patent families filed across US, EP, JP, CN, CA, KR, and AU; estate reconciled at 83+ claims.
OIN membership confirmed, extending defensive patent coverage.
LOT Network membership confirmed.
Laboratory-environment validation of the ERIONEX OS minimum viable product.
Seed financing closed to advance the platform toward field validation.
Stated intent; timing and terms not yet finalized.
Holistic Therapeutics-as-a-Service is the commercial surface through which the architecture above becomes a product sponsors, CROs, and regulators can actually consume.
Built against the standards matrix above rather than retrofitted to it.
MVP validated in a laboratory environment, advancing toward field validation.
Provisional patent protection filed ahead of broader platform disclosure.
The ERIONEX Foundation, an open governance initiative hosting the Planetary Therapeutic Memory standard, brings together sovereign health ministries, academic medical institutions, and regulatory agencies to treat global therapeutic intelligence data as a shared public good.
Forward · Foundation currently in developmentDetailed architecture specifications, full claim language, control-level compliance mappings, and financial materials are disclosed only under a mutual non-disclosure agreement.
Whether you are an investor, a potential pharma or CRO partner, a regulator, a journalist, or someone who wants to join the mission, we want to hear from you.
Qualified investors may request access to due diligence materials: financial model, cap table, IP portfolio, and technical architecture, all provided under NDA. Secure portal coming post-seed.
Request NDA access → $14M seed round inquiry →If you are a pharmaceutical company or CRO interested in early platform access, a strategic partnership discussion, or our pilot programme, we would welcome the conversation.
Pilot programme, expressions of interest now open Express pilot interest → Strategic partnership →Journalists, analysts, and researchers covering pharmaceutical AI, Canadian technology innovation, or sovereign health infrastructure are welcome to reach out for background information.
info.erionex@gmail.com →Our leadership team spans pharmaceutical medicine, clinical operations, and global regulatory affairs. We are now building the engineering, AI research, and advisory layers. If you want to build something that matters for the next 500 years, we want to hear from you.
Engineering & research roles →We are forming our Clinical Advisory Board and Technical Advisory Board, bringing together the world’s foremost minds in pharmaceutical development, regulatory science, and therapeutic AI. Nominations and expressions of interest are welcome.
Nominate or express interest →